Interactions between Upf1 and the Decapping Factors Edc3 and Pat1 in *Saccharomyces cerevisiae*

Kylie D. Swisher²; Roy Parker¹,²*

¹Howard Hughes Medical Institute, University of Arizona, Tucson, Arizona, United States of America, ²Department of Molecular and Cellular Biology, University of Arizona, Tucson, Arizona, United States of America

Abstract

In *Saccharomyces cerevisiae*, mRNA transcripts with premature termination codons are targeted for deadenylation independent decapping and 5' to 3' decay in a quality control pathway termed nonsense-mediated decay (NMD). Critical factors in NMD include Upf1, Upf2, and Upf3, as well as the decapping enzyme, Dcp2/Dcp1. Loss of Upf2 or Upf3 leads to the accumulation of not only Upf1 and Dcp2 in P-bodies, but also of the decapping-activators Pat1, Dhh1, and Lsm1. An interaction between Upf1 and Dcp2 has been identified, which might recruit Dcp2 to the NMD decapping complex. To determine the nature and significance of the Dcp2-Upf1 interaction, we utilized the yeast two-hybrid assay to assess Upf1 interactions with various mRNA decapping factors. We find that although Dcp2 can interact with Upf1, this interaction is indirect and is largely dependent on the Edc3 protein, which interacts with the N-terminal domain of Upf1 at an overlapping, but not identical, site as Upf2. We also found that Pat1 has an independent two-hybrid interaction with the N-terminus of Upf1. Assessment of both reporter and endogenous NMD transcripts suggest that the decapping stimulators, including Edc3 and Pat1, as well as Edc1 and Edc2, are not essential for NMD under normal conditions. This work defines a larger decapping complex involved in NMD, but indicates that components of that complex are not required for general NMD and might either regulate a subset of NMD transcripts or be essential for proper NMD under different environmental conditions.

Introduction

An important mRNA quality control pathway in eukaryotic cells is the nonsense-mediated decay (NMD) pathway, whereby transcripts with aberrant termination codons are targeted for degradation. This process prevents the potentially toxic build-up of aberrant peptides that can arise from mRNA transcripts with premature termination codons (PTCs) [1]. NMD targets mRNAs with PTCs that can arise by many mechanisms, including poor transcription fidelity, frameshift mutations, and inefficiently spliced intron-containing mRNAs that are transported to the cytoplasm [reviewed in 2]. In the yeast, *Saccharomyces cerevisiae*, transcripts that contain these PTCs are predominantly targeted by deadenylation independent decapping and 5' to 3' degradation [3,4].

In eukaryotes, including mammalian cells, *Drosophila*, *Caenorhabditis elegans* and yeast, the core NMD machinery is comprised of the factors Upf1, Upf2, and Upf3, which are all essential for NMD to occur in the cytoplasm [5,6, reviewed in 7]. Interaction between Upf1 and Upf2 and between Upf2 and Upf3 has been demonstrated previously by yeast two-hybrid analysis [6,8,9] and by co-immunoprecipitation experiments [10,11,12]. Recently, crystal structures of mammalian Upf2 bound to Upf1 have demonstrated that hUpf2 directly interacts with the N-terminal cysteine-histidine-rich domain of hUpf1 in a unique bipartite manner [13]. In *vivo* analyses of hUpf2 mutations that disrupt this Upf1-Upf2 interaction surface subsequently inhibit NMD of a reporter transcript Globin 6MS2 [13]. Similarly, crystal structures of mammalian Upf3 bound to Upf2 demonstrate that hUpf3 binds hUpf2 just N-terminal of the hUpf1 binding site [14]. These results provide evidence for the importance of the interactions between the three Upf proteins in promoting and regulating NMD.

Along with the core Upf machinery, the decapping enzyme, Dcp2/Dcp1, is also important for NMD in yeast [3,15]. Loss of Dcp1 or Dcp2 leads to defects in NMD of both endogenous and reporter transcripts [3,16]. Additionally, loss of Upf2 or Upf3 leads to the accumulation of both Upf1 and Dcp2 in P-bodies [17]. Here, NMD is impaired by the loss of Upf2 or Upf3, but Dcp2 still appears to be recruited to the site of Upf1 localization. Since a Dcp2-Upf1 interaction has been identified by a high-throughput protein-fragment complementation assay (PCA) in yeast [18], one possibility is that this Dcp2-Upf1 interaction recruits Dcp2 to the mRNA for decapping stimulated by Upf1.

Interestingly, loss of Upf2 and Upf3 also leads to accumulation of other factors, including Xrn1, Dhh1, Pat1, and Lsm1 in P-bodies [17]. Dhh1, Pat1, and Lsm1 are all activators of the decapping enzyme in *vivo* [19,20,21]. This suggests that a larger decapping complex consisting of the decapping enzyme and its associated factors may form during NMD. Providing further support for this model, interaction between Upf1 and Dhh1 has...
### A.

|         | Empty Vector | Dcp2 (1-300) | Dcp2 (102-300) | Dcp2 (1-245) | Dcp2 (102-245) |
|---------|--------------|--------------|----------------|--------------|----------------|
| Empty Vector | ![Image](image1) | ![Image](image2) | ![Image](image3) | ![Image](image4) | ![Image](image5) |
| Dcp2 (1-300) | ![Image](image6) | ![Image](image7) | ![Image](image8) | ![Image](image9) | ![Image](image10) |
| Dcp2 (102-300) | ![Image](image11) | ![Image](image12) | ![Image](image13) | ![Image](image14) | ![Image](image15) |
| Dcp2 (1-245) | ![Image](image16) | ![Image](image17) | ![Image](image18) | ![Image](image19) | ![Image](image20) |
| Dcp2 (102-245) | ![Image](image21) | ![Image](image22) | ![Image](image23) | ![Image](image24) | ![Image](image25) |

|         | Upf1 Nt |
|---------|---------|
| Dcp2 (1-300) | - |
| Dcp2 (102-300) | + |
| Dcp2 (1-245) | - |
| Dcp2 (102-245) | - |

### B.

|         | Empty Vector | Dcp2 (102-300) (WT) | Dcp2 (102-300) Mut. 19 | Dcp2 (102-300) Mut. 21 |
|---------|--------------|----------------------|------------------------|------------------------|
| Empty Vector | ![Image](image26) | ![Image](image27) | ![Image](image28) | ![Image](image29) |
| Dcp2 (102-300) (WT) | ![Image](image30) | ![Image](image31) | ![Image](image32) | ![Image](image33) |
| Dcp2 (102-300) Mut. 19 | ![Image](image34) | ![Image](image35) | ![Image](image36) | ![Image](image37) |
| Dcp2 (102-300) Mut. 21 | ![Image](image38) | ![Image](image39) | ![Image](image40) | ![Image](image41) |

|         | Empty Vector | Dcp2 (102-300) WT | Dcp2 Mutant 19: L255A, K256A | Dcp2 Mutant 21: E252A, L255A, K256A |
|---------|--------------|------------------|--------------------------------|----------------------------------|
| Empty Vector | ![Image](image42) | ![Image](image43) | ![Image](image44) | ![Image](image45) |
| Dcp2 (102-300) WT | ![Image](image46) | ![Image](image47) | ![Image](image48) | ![Image](image49) |
| Dcp2 Mutant 19: L255A, K256A | ![Image](image50) | ![Image](image51) | ![Image](image52) | ![Image](image53) |
| Dcp2 Mutant 21: E252A, L255A, K256A | ![Image](image54) | ![Image](image55) | ![Image](image56) | ![Image](image57) |

|         | Upf1 Nt | Edc3 FL |
|---------|---------|---------|
| Empty Vector | - | - |
| Dcp2 (102-300) WT | + | + |
| Dcp2 Mutant 19: L255A, K256A | - | - |
| Dcp2 Mutant 21: E252A, L255A, K256A | - | - |

### C.

|         | Wild-type | edc3Δ |
|---------|-----------|-------|
| Empty Vector | ![Image](image58) | ![Image](image59) |
| Dcp2 (102-300) | ![Image](image60) | ![Image](image61) |
| Upf2 Ct | ![Image](image62) | ![Image](image63) |
| Pat1 Ct | ![Image](image64) | ![Image](image65) |

|         | Wild-type | edc3Δ |
|---------|-----------|-------|
| Empty Vector | ![Image](image66) | ![Image](image67) |
| Dcp2 (102-300) | ![Image](image68) | ![Image](image69) |
| Upf2 Ct | ![Image](image70) | ![Image](image71) |
| Pat1 Ct | ![Image](image72) | ![Image](image73) |

|         | Wild-type | edc3Δ |
|---------|-----------|-------|
| Empty Vector | ![Image](image74) | ![Image](image75) |
| Dcp2 (102-300) | ![Image](image76) | ![Image](image77) |
| Upf2 Ct | ![Image](image78) | ![Image](image79) |
| Pat1 Ct | ![Image](image80) | ![Image](image81) |

|         | Wild-type | edc3Δ |
|---------|-----------|-------|
| Empty Vector | ![Image](image82) | ![Image](image83) |
| Dcp2 (102-300) | ![Image](image84) | ![Image](image85) |
| Upf2 Ct | ![Image](image86) | ![Image](image87) |
| Pat1 Ct | ![Image](image88) | ![Image](image89) |

|         | Wild-type | edc3Δ |
|---------|-----------|-------|
| Empty Vector | ![Image](image90) | ![Image](image91) |
| Dcp2 (102-300) | ![Image](image92) | ![Image](image93) |
| Upf2 Ct | ![Image](image94) | ![Image](image95) |
| Pat1 Ct | ![Image](image96) | ![Image](image97) |

|         | Wild-type | edc3Δ |
|---------|-----------|-------|
| Empty Vector | ![Image](image98) | ![Image](image99) |
| Dcp2 (102-300) | ![Image](image100) | ![Image](image101) |
| Upf2 Ct | ![Image](image102) | ![Image](image103) |
| Pat1 Ct | ![Image](image104) | ![Image](image105) |

|         | Wild-type | edc3Δ |
|---------|-----------|-------|
| Empty Vector | ![Image](image106) | ![Image](image107) |
| Dcp2 (102-300) | ![Image](image108) | ![Image](image109) |
| Upf2 Ct | ![Image](image110) | ![Image](image111) |
| Pat1 Ct | ![Image](image112) | ![Image](image113) |
been seen by the high-throughput PCA in yeast and between Upf1 and Lsm1 by a high-throughput affinity capture and mass spectroscopy assay [18,22]. However, the available evidence suggests that both Dhh1 and Pat1 are expendable for proper NMD in yeast, as NMD was not impaired in a dhh1Δpat1Δ double deletion strain [23]. This does not rule out that Dhh1 or Pat1 may have a redundant role in NMD with other decapping-associated factors.

In yeast, several additional factors exist that associate with the decapping enzyme and also stimulate or enhance its activity. Among these are the enhancers of decapping factors, Edc1, Edc2, and Edc3. These factors are capable of binding RNA and stimulating the activity of Dcp2/Dep1 [24–27]. Previous evidence suggests that Edc3 alone is not essential for proper NMD in yeast [28]. However, it has not been determined if Edc1, Edc2, or Edc3 individually or in some combination can affect NMD. Therefore, it is possible that these stimulators of decapping also comprise the larger decapping complex that co-localizes with Upf1 in P-bodies and may regulate NMD in a redundant manner with other decapping-associated factors in yeast.

Since both Upf1 and Dcp2/Dep1 are essential for NMD in yeast, we set out to understand the Upf1 interaction with the decapping enzyme and the broader decapping complex. To do this, we utilized the yeast two-hybrid assay to assess interactions of Upf1 with Dcp2, Pat1, Dhh1 and Edc3. We find that the N-terminal cysteine-histidine-rich domain of Upf1 interacts with Edc3, Pat1, and Dcp2 by two-hybrid, although the Dcp2 interaction with Upf1 is largely mediated by Edc3. Interestingly, Edc3 and Upf1 bind to Upf1 at overlapping, but not identical sites.

To understand the function of these interactions, we assessed NMD of endogenous and reporter transcripts upon loss of these decapping stimulators. We also used Upf1 mutants disrupted for Upf1-Edc3 and/or Upf1-Upf2 interaction to assess the role of the Upf1-Edc3 interaction in NMD. The results obtained suggest that the decapping stimulators are not essential for NMD during normal growth conditions. However, given that both Pat1 and Edc3 associate with Upf1, and that decapping-associated factors are localized to Upf1- and Dcp2-containing foci upon loss of Upf2 or Upf3, it is possible that these decapping stimulators affect a subset of NMD transcripts or have essential roles for NMD under different conditions.

Results

Dcp2 interacts with the Upf1 N-terminal domain through Edc3

The first step in understanding how the decapping complex is recruited to Upf1-bound, aberrant PTC-containing mRNAs is to assess if an interaction, whether direct or indirect, exists between Upf1 and the decapping enzyme, Dcp2. While this interaction was found by the high-throughput PCA method [18], we took advantage of the yeast two-hybrid system to assess their association by an alternative method. Yeast Dcp2 is 970 amino acids long but only the first 300 amino acids are required for decapping [16,29]. Given this, we tested whether we could observe a two-hybrid interaction between Upf1 and either Dcp2 1–300 or Dcp2 102–300. We observed a clear interaction between the Upf1 N-terminal region (binding domain) and the catalytic domain of Dcp2 (residues 102–300) (Figure 1A). We did not see an interaction with Dcp2 1–300, but western analysis showed that this construct was not expressed well (data not shown). No interaction was seen when Upf1 full-length was used, a likely result of either improper folding of the Upf1 protein or blockage of the interaction site when Upf1 full-length was tethered to the β-galactosidase binding domain. For this reason, we utilized the N-terminal cysteine-histidine domain of Upf1, as it is highly conserved and contains the Upf2 binding site [30]. These results identified a two-hybrid interaction between the N-terminal domain of Upf1 and the 102–300 region of Dcp2.

Additional constructs revealed that the 245–300 region of Dcp2, which is an unstructured extension [31], was required for the interaction with Upf1 (Figure 1A). The critical observation was that the 102–300 region of Dcp2 interacted strongly with Upf1, whereas the 102–245 region of Dcp2 did not interact, despite being well expressed based on western analysis (data not shown). Interestingly, this region has previously been identified to contain the amino acids required for interaction with the decapping stimulator, Edc3 [27,29], raising the possibility that the observed two-hybrid interaction between Dcp2 and Upf1 is through Edc3.

Three additional observations confirm that Upf1 interacts with Dcp2 through Edc3. First, Dcp2 mutants L255A K256A (Dcp2 Mutant 19) and E252A, L255A, K256A (Dcp2 mutant 21) are known to disrupt Dcp2-Edc3 interactions [29] and they reduce the two-hybrid interaction of Dcp2 and Upf1 (Figure 1B). Second, the Upf1-Dcp2 two-hybrid interaction is strongly reduced in an edc3Δ strain (Figure 1C). This result suggests that Edc3 may function with additional factors to mediate the Upf1-Dcp2 interaction. Finally, we also observed a two-hybrid interaction of Edc3 with Upf1 N-terminal domain (Figure 2A). Taken together, we interpret these results to indicate that Edc3 interacts, directly or indirectly, with Upf1 and thereby can promote a Dcp2-Upf1 interaction.

The Edc3 binding site of Upf1 overlaps with a predicted Upf2 binding site

To determine how Edc3 interacted with Upf1, we sought to map the interaction site of Edc3 on Upf1 at the amino acid level. To do this, we constructed Upf1 mutants containing one to four alanine substitutions. The crystal structure of mammalian Upf1 (PDB code 2IYK) [13] was used to predict the structure of S. cerevisiae Upf1 (Figure 2B), following which the SASA values were calculated using the areaimol program (SASA analysis was kindly provided by John Gross at UCSF). The two Upf2-binding sites were predicted based upon the mammalian Upf1-Upf2 binding data and are highlighted in yellow on the S. cerevisiae Upf1 predicted structure (Figure 2B) [13]. The predicted structure of Upf1, along with the SASA values allowed us to construct a series of mutations along the surface of the yeast Upf1 protein between residues 60–208.

Upon testing these Upf1 mutants (binding domain) for interaction with full-length Edc3 (activation domain) by yeast two-hybrid, we identified five mutants that disrupted the Upf1-
Figure 2. Edc3, Upf2 and Pat1 all interact with the N-terminal domain of Upf1; Edc3 and Upf2 do so in an overlapping, but not identical manner. (A and B) Dcp2 (102–300), Edc3 FL, Upf2 Ct, and Pat1 Ct were all assessed for their ability to interact with Upf1 Nt (WT) by yeast two-hybrid analysis. Interactions between Upf1 Nt and Dcp2 (102–300), Edc3 FL, and Upf2 Ct were further characterized at the amino acid level. The interactions between Upf1 and Edc3/Pat1 in Yeast.
Edc3 interaction. Mutants 3 (Q166A, E170A, L175A W177A), 18 (P111A, D112A, D114A, D117A), 23 (L115A, Y123A), 24 (W177A), and 27 (L115A, Y123A, W177A, VVVL143AAA) all showed inhibition of the Upf1-Edc3 interaction (Figure 2A). Expression of all five of these mutant proteins was similar or greater than wild-type Upf1, indicating that the defect in interaction was not due to poor expression of the constructs (data not shown). Additional mutants covering the remainder of the Upf1 N-terminal domain surface did not affect the Upf1-Edc3 interaction (data not shown). The defect in Edc3-Upf1 interaction in these mutants defines the regions of Upf1 required for the Edc3-Upf1 interaction.

Interestingly, this putative binding site of Edc3 on Upf1 partially overlaps with the Upf2 binding surfaces. Specifically, mutants 23, 24, and 27 contain alanine substitutions of residues that are predicted to be within one of the two Upf2 binding surfaces (Figure 2; dark blue, orange, and light blue, respectively). Upf1 mutants 3 and 18 reside near this predicted Upf2 binding surface (Figure 2B; pink and green, respectively). These results suggest that Edc3 interacts with Upf1 at or near one of the predicted Upf2 binding sites. We also made amino acid substitutions in the second predicted Upf2 binding surface on Upf1, but were unable to assess their function as they were all poorly expressed (data not shown).

Additionally, we assayed the binding pattern of Dcp2 on Upf1 by the yeast two-hybrid assay. If Edc3 is mediating this interaction, the Dcp2-Upf1 interaction should show a similar binding pattern as Edc3 does on Upf1. Upf1 Mutants 3, 23, 24, and 27 all showed strong inhibition of the Upf1-Dcp2 interaction (Figure 2A). Mutant 18 also inhibited the Upf1-Dcp2 interaction, although to a lesser extent (Figure 2A). Therefore, the mutations that disrupt the Edc3-Upf1 interaction also disrupt the Dcp2-Upf1 interaction, providing further evidence that Edc3 mediates the Upf1-Dcp2 interaction.

Edc3 and Upf2 share overlapping, but not identical, binding sites on Upf1

Our results suggest that Edc3 interacts with the N-terminus of Upf1 at or near the predicted binding sites of Upf2. To test this, we assayed the binding ability of Upf2 C-terminus with the Upf1 mutants by yeast two-hybrid. As seen in Figure 2A, only Upf1 mutant 27, which contains alanine substitutions for many of the residues in the predicted Upf2 binding surface, showed strong inhibition of the Upf1-Upf2 interaction. Mutants 3 and 23 also showed some weak disruption of the Upf1-Upf2 interaction, while mutants 18 and 24 showed wild-type levels of interaction. These results suggest that the Edc3 and Upf2 binding sites on Upf1 likely overlap, although not perfectly.

To determine if the Upf1-Edc3 interaction was through Upf2, we deleted Upf2 in the yeast two-hybrid strain background and assayed for the ability of Edc3 to interact with Upf1. Loss of Upf2 did not affect the positive interaction between Edc3 and Upf1 (Figure 2C). We also wanted to verify that the Upf1-Upf2 interaction was not affected by Edc3. To test this, we tested the Upf1-Upf2 two-hybrid interaction in an edc3Δ strain. Loss of Edc3 did not disrupt the positive interaction of Upf2 and Upf1 (Figure 1C). Interestingly, our yeast two-hybrid results consistently suggested a heightened interaction between Upf1 and Upf2 upon loss of Edc3. These results therefore support the conclusion that Edc3 and Upf2 independently interact at partially overlapping sites on Upf1.

Upf1 interacts with decay factor Pat1

We have identified an interaction between Upf1 and the decapping-associated factor, Edc3. We therefore wanted to test if Upf1 might interact with other decay factors, such as Pat1 and Dhh1. Pat1 is a translational repressor that can bind to RNA and also stimulate mRNA decapping by Dcp2 [27,32]. Dhh1 is also a translational repressor that can bind to RNA and activate decapping in vivo [21,27,33]. We used the yeast two-hybrid system to assay interaction between Upf1 and these two translational repressors.

Our results suggest that Upf1 can interact with Pat1 but not Dhh1 (Figure 2A, data not shown). Specifically, Upf1 interacts with the C-terminal (Ct) domain of Pat1 (Figure 2A). We must note that we were unable to confirm interaction between Upf1 and full-length Pat1, as it showed positive interaction with the empty vector alone. However, the C-terminal domain of Pat1 only showed positive interaction with the N-terminal domain of Upf1, and not the empty vector.

Since both Dcp2 and Upf1 interact with Pat1 at its Ct domain, it is possible that Pat1 also mediates the Upf1-Dcp2 interaction. To test this, we constructed a Pat1 deletion in the yeast two-hybrid strain background and assayed for ability of Dcp2 and Upf1 to interact. Loss of Pat1 did not disrupt interaction of Dcp2 with Upf1 (Figure 2D). Likewise, interaction of Upf1 with both Edc3 and Upf2 was not disrupted by loss of Pat1 (Figure 2D). This suggests that Pat1 does not recruit the decapping enzyme to Upf1, nor does it mediate the Upf1-Edc3 and Upf1-Upf2 interactions.

We also wanted to verify that the Pat1-Upf1 interaction was not through another known Upf1-interacting protein. To determine this, we tested the Pat1-Upf1 interaction in upf2Δ and edc3Δ strains. Pat1 was still able to associate with Upf1 in the absence of either Upf2 (Figure 2C) or Edc3 (Figure 1C). Therefore, Pat1 is yet another factor that may directly associate with the N-terminal domain of Upf1.

Taken together, we have identified independent two-hybrid interactions of the Upf1 N-terminal domain with Edc3 and Pat1, which are also independent of the Upf2-Upf1 interaction. The Edc3-Upf1 interaction partially overlaps with the Upf2 binding site on Upf1. Finally, the interaction of Edc3 with Upf1 can promote a Dcp2-Upf1 interaction, at least in the two-hybrid assay.

Upf1-Edc3 and Upf1-Pat1 interactions are not required to promote NMD

The interactions between Edc3, Pat1, and Upf1 are not simply required for NMD since both edc3Δ and pat1Δ strains show normal NMD [28,34]. However, it remained possible that Edc3 and Pat1 have redundant roles in recruiting Dcp2 to Upf1 in NMD, which would suggest that an edc3Δ pat1Δ double mutant might have a defect in NMD.

To determine if Edc3 and Pat1 could have a redundant role in NMD, we utilized a galactose-inducible PGK1c103 NMD
construct. This construct contains an added sequence that allows for detection of the PTC-containing PGK1c103 independent from the normal PGK1 transcript that is present in the $edc3\Delta$ $pat1\Delta$ strain [3]. Our results suggest that Edc3 and Pat1 together do not have a significant role in promoting normal NMD, as degradation of PGK1c103 in the $edc3\Delta$ $pat1\Delta$ strain is only very slightly slower than degradation in the wild-type strain (Figure 3A). Additional analysis of CYH2 steady-state pre-mRNA/mRNA ratios in $edc3\Delta$ $pat1\Delta$ and wild-type strains showed normal levels of NMD upon loss of both Edc3 and Pat1 (Figure 3B).

We also tested if Edc3 might be redundant with Edc1 or Edc2, which can also directly stimulate activity of Dcp2 [24,25,27], and observed that even the triple mutant $edc1\Delta$ $edc2\Delta$ $edc3\Delta$ showed normal NMD (Figure 3C). These results, combined with the fact that single deletions of Edc3 and Pat1 have no affect on NMD suggest that the Edc3-Upf1 and Pat1-Upf1 interactions are not required for NMD.

Consistent with Edc3-Upf1 interactions not being required for NMD, we also observed that mutations in Upf1 that disrupted interactions with Edc3 did not affect the decay of a PGK1 nonsense-containing reporter, gal-PKG1c142. Specifically, Upf1 mutants 3, 23, and 24, which disrupt the Edc3-Upf1 interaction to a significant extent but have little to no effect on the Upf1-Upf2 interaction, showed no change in decay rate of PGK1c142 compared to wild-type Upf1 (Figure 4A). Similar results were also obtained when the levels of the pre-CYH2 mRNA were compared, as Upf1 mutant 27 was the only mutant to show an increase in pre-mRNA levels (Figure 4B). These results suggest that the Upf1-Edc3 interaction is not required for recruitment of Dcp2 to the NMD substrate and confirm earlier studies that suggest a requirement of Upf2 interaction with Upf1 for proper NMD [8,13].

Edc3-Upf1 interaction does not negatively regulate NMD

The partial overlap of the Edc3 and Upf2 binding sites on Upf1 suggested the hypothesis that Edc3-Upf1 interaction might be a negative regulatory interaction that inhibits decapping in NMD and this negative regulation would be relieved by Upf2-Upf1 interaction competing with the Edc3-Upf1 interaction. In this model, the purpose of the Edc3-Upf1 interaction is not to simply recruit Dcp2 to an mRNA target, but instead, to inhibit decapping until a specific time designated by the release of Edc3 from its association with Upf1 due to the Upf1-Upf2 interaction. Therefore, we reasoned that loss of the Edc3-Upf1 interaction should suppress any defect in NMD triggered by impaired Upf1-Upf2 interaction. In an attempt to determine if the Edc3-Upf1 interaction is inhibitory and if Upf2 is the ‘switch’ that releases Edc3 from Upf1, we utilized two different assays.

First, we tested the decay rate of the nonsense codon transcript, PGK1c142, in the presence of Upf1 mutants defective in the
interaction with Edc3 and in the absence of Upf2. If decay rates are significantly altered with the Upf1 mutants compared to wild-type Upf1 in a upf2Δ strain background, it would suggest that Upf2 functions as the ‘switch’ to trigger Edc3 release. Additionally, the absence of Upf2 allows for easier detection of changes in decay rates due to its impairment of NMD [6,17]. We monitored decay of PGK1c142 by galactose shut-off experiments to assay the effect of our Upf1 mutants in the upf1Δ upf2Δ strain. The decay rates of PGK1c142 were comparable between wild-type Upf1 and all five of the Upf1 mutants tested (Figure 5A). Additionally, CITH2 steady-state pre-mRNA/mRNA levels were comparable between wild-type Upf1 and the Upf1 mutants in the upf1Δ upf2Δ background (Figure 5B). These results suggest that the Edc3-Upf1 interaction is not inhibitory and relieved by the Upf1-Upf2 interaction.

Second, we analyzed decay of CITH2 in the presence of Upf2 mutants defective for Upf1 association, NMD, or both. Upf2 may have an additional role in NMD independent of the Upf1-Upf2 interaction, so we utilized Upf2 mutants to better assess the requirement for a ‘switch’ in NMD. Thus, in the presence of the Upf2 mutants defective in NMD it is possible that we can sidestep the requirement for the ‘switch’ by disrupting the Edc3-Upf1 interaction. This should potentially lead to the suppression of the NMD defects caused by mutations in Upf2. To do this experiment, we compared the steady-state ratio of CITH2 pre-mRNA/mRNA when Upf2 mutants were present with either wild-type Upf1 or Upf1 mutant 27 (defective in Edc3-Upf1 and Upf2-Upf1 interaction). Four different classes of Upf2 mutants were utilized [8]: 1) Mutants which still interact with Upf1 by yeast two-hybrid assay and show wild-type levels of NMD (Upf2 M13). 2) A mutant which showed significant reduction in the Upf2-Upf1 interaction but still showed wild-type levels of NMD (Upf2 M6-NE). 3) A mutant which interacts at wild-type levels with Upf1 but shows a defect in NMD (Upf2 M6-G). 4) Mutants which both impair the Upf2-Upf1 interaction and lead to defects in NMD (Upf2 M5).

Our results suggest that the Edc3-Upf1 interaction does not have an inhibitory role on NMD, as Upf1 mutant 27 did not suppress the NMD defects caused by Upf2 mutants with inefficient NMD (Figure 5C). Rather, Upf1 mutant 27 lead to impairment of NMD in the presence of both wild-type Upf2 and Upf2 mutants that were still able to undergo moderate to normal levels of NMD. In conjunction with Upf1 mutant 27, class 1 Upf2 M13 and class 2 Upf2 M6-NE showed impaired NMD compared to wild-type Upf1 levels. Class 3 Upf2 M6-G showed higher levels of NMD in the presence of wild-type Upf1 in our hands compared to that which was previously published [8], and this was impaired in the presence of Upf1 mutant 27. Lastly, class 4 Upf2 M5, which showed impaired NMD with wild-type Upf1, likewise showed impaired NMD with Upf1 mutant 27. There was a slight suppression of the NMD defect in the presence of Upf1 mutant 27, but not a significant reduction. Thus, it appears that Upf1 mutant 27 leads to further defects in NMD and does not sufficiently suppress defects caused by Upf2 mutants. This provides additional evidence against an inhibitory role for the Edc3-Upf1 interaction.

However, it is possible that Upf1 mutant 27 does not suppress the Upf2 mutants because we have insufficiently disrupted the Edc3-Upf1 interaction by the specific mutations we used in Upf1. Therefore, to be sure that the Edc3-Upf1 interaction is eliminated, we constructed an edc3Δ upf2Δ strain to test if the loss of Edc3 could suppress the NMD defects of the Upf2 mutants. Loss of Edc3 does not alter the NMD phenotypes of the Upf2 mutants (Figure 5D). Therefore, our results suggest that the Edc3-Upf1 interaction does not impair decapping of NMD targets by blocking Dcp2 function, thereby confirming results obtained by analysis of PGK1c142 mRNA in the absence of Upf2 and results obtained using Upf1 mutant 27 in conjunction with the Upf2 mutants.

**Discussion**

**Nature of the NMD decapping complex**

In yeast, efficient NMD of aberrant mRNA transcripts is dependent upon the decapping enzyme Dcp2/Dcp1, but the mechanism by which the decapping enzyme associates with the mRNA is unknown. Herein, we have identified interactions...
Figure 5. The Edc3-Upf1 interaction is not a negative regulator of NMD. (A) NMD of the PTC-containing galactose-inducible reporter transcript, gal-PGK1c142, was assessed in a upf1Δ upf2Δ double deletion strain containing either empty vector, Upf1 wild-type, Upf1 mutant 3, Upf1 mutant 18, Upf1 mutant 23, Upf1 mutant 24, or Upf1 mutant 27 on a plasmid. (B) Steady-state pre-mRNA/mRNA ratios of the endogenous NMD transcript, CYH2, were assessed in the upf1Δ upf2Δ strain containing either wild-type Upf1, empty vector, Upf1 mutant 3, Upf1 mutant 18, Upf1 mutant 23, Upf1 mutant 24, or Upf1 mutant 27 on a plasmid. (C) Steady-state pre-mRNA/mRNA ratios of CYH2 were assessed in a upf1Δ upf2Δ strain containing either wild-type Upf1 or Upf1 mutant 27 and either Upf2 mutant 13, Upf2 mutant 6-NE, Upf2 mutant 6-G, empty vector, or Upf2 wild-type plasmids. (D) Steady-state pre-mRNA/mRNA ratios of CYH2 were assessed in an upf2Δ and an edc3Δ upf2Δ strain containing either Upf2 mutant 13, Upf2 mutant 6-NE, Upf2 mutant 6-G, Upf2 mutant 5, empty vector, or Upf2 wild-type plasmids.

doi:10.1371/journal.pone.0026547.g005
between the decapping stimulators, Edc3 and Pat1, and Upf1. Interaction of both of these factors occurs on the N-terminal domain of Upf1. Dcp2 interacts with both Edc3, via the Edc3 Lsm domain, and Pat1 via the middle and C-terminal domains of Pat1 [27,35]. This raises the possibility that Edc3 and/or Pat1 may be bridging an interaction between Upf1 and Dcp2/Dcp1. Our yeast two-hybrid results suggest that Edc3, but not Pat1, mediates the Upf1-Dcp2 interaction. These results argue that Upf1 can interact with Edc3 and Upf2 by yeast two-hybrid. We find that the Edc3-Upf1 interaction is disrupted when residues at or near one of the two predicted Upf2-binding sites are mutated. One of these five mutants, which contains alanine substitutions at ~80% of the residues within this predicted Upf2-binding site, also disrupted the Upf1-Upf2 interaction. Further, we confirmed that Upf1 interaction with both Edc3 and Upf2 is not mediated by the opposite factor. This argues that Edc3 and Upf2 share overlapping, although not identical, binding sites on the N-terminal domain of Upf1.

There are two potential models for how Edc3 and Upf2 might interact at an overlapping site on Upf1. One possibility is that these interactions occur on the same mRNA substrate but at a different stage of the NMD process. Alternatively, these interactions occur on the same mRNA substrate but at a different stage of the NMD process. Alternatively, these interactions occur on the same mRNA substrate but at a different stage of the NMD process.
Significance of Upf1 interaction with decapping stimulators

Upon investigating the role of the interaction of Upf1 with the decapping stimulators, Edc3 and Pat1, we found that neither the Upf1-Edc3 nor the Upf1-Pat1 interactions were essential for NMD. Additionally, we found that Edc3 and Pat1 do not have redundant roles with each other in promoting NMD, as NMD of both a reporter transcript and an endogenous NMD substrate was not altered in an edc3Δ pat1Δ strain. Upon examining the role of additional decapping stimulators in NMD, we also found that Edc1 and Edc2 were dispensable for NMD. These results strongly argue that decapping stimulators are not required for global NMD in yeast, and raise the possibility that Edc3-Upf1 interaction might regulate a different pool of mRNAs.

One possibility was that the interaction between Edc3 and Upf1 functioned as a negative regulator of NMD. In this model, the Upf1-Edc3 interaction is required to prevent the stimulation of Dcp2 decapping activity on NMD substrates. If this interaction does serve an inhibitory role, some signal must be present to trigger release of Edc3, and subsequently Dcp2, in a temporally dependent manner. The overlapping binding sites of Edc3 and Upf2 on Upf1 suggest that Upf2 may provide the ‘switch’ to trigger release of Edc3 and degradation of the NMD substrate. Upon testing this switch model, we find that the Upf1-Edc3 interaction does not confer negative regulation. Here, disruption of the Upf1-Edc3 interaction did not suppress NMD defects caused by loss of the Upf1-Upf2 interaction. This argues that Edc3 does not negatively regulate NMD, as simple release of Edc3 from Upf1 is not capable of triggering NMD when it is impaired by disrupted Upf1-Upf2 association.

These results raise the question as to the significance of the Upf1 interaction with both Edc3 and Pat1. Additionally, if these interactions are dispensable for NMD, why would loss of Upf2 or Upf3 lead to their accumulation with Upf1 and Dcp2 in cytoplasmic P-bodies [17]? We envision a couple of possible roles for the Upf1-Edc3 and/or Upf1-Pat1 interactions. 1) Edc3 and/or Pat1 might associate with Upf1 to regulate a subset of NMD transcripts. 2) Edc3 and/or Pat1 may be essential for promoting NMD when environmental or growth conditions are altered. It is possible that under normal conditions, Dcp2 is efficiently recruited

| Plasmids       | Properties                          | References                                                      |
|---------------|-------------------------------------|----------------------------------------------------------------|
| pRP1289       | pOBD-II (Binding domain empty vector) | [37]; provided by Stanley Fields, Yeast Resource Center         |
| pRP1290       | pOAD (Activating domain empty vector) | [37]; provided by Stanley Fields, Yeast Resource Center         |
| pRP2277       | AD-Upf1 N-terminus (1–230)          | This Study                                                     |
| pRP2278       | AD-Dcp2 (102–300)                   | Recovered from yRP2366, [35]                                   |
| pRP2279       | AD-Dcp2 (1–245)                     | This Study                                                     |
| pRP2280       | AD-Dcp2 (102–245)                   | This Study                                                     |
| pRP2281       | AD-Dcp2 (102–300) Mutant 19: L255A K256A | This Study                                                   |
| pRP2282       | AD-Dcp2 (102–300) Mutant 21: E252A L255A K256A | This Study                                                   |
| pRP2283       | AD-Edc3 Full-length                 | Recovered from yRP2368, [35]                                   |
| pRP2284       | AD-Upf2 C-terminus (Ct 157 AA)      | This Study                                                     |
| pRP1511       | BD-Pat1 C-terminus (∆10-422)        | [32]                                                          |
| pRP2285       | AD-Upf1 N-terminus (1–230)          | This Study                                                     |
| pRP2286       | BD-Upf1 Mutant 3: Q166A E170A L175A W177A | This Study                                                   |
| pRP2287       | BD-Upf1 Mutant 18: P111A D112A D114A D117A | This Study                                                   |
| pRP2288       | BD-Upf1 Mutant 23: L115A Y123A        | This Study                                                     |
| pRP2289       | BD-Upf1 Mutant 24: W177A             | This Study                                                     |
| pRP2290       | BD-Upf1 Mutant 27: L115A Y123A W177A VVVL143AAAA | This Study                                                   |
| pRP249        | prS415 empty vector; cen; leu       | [39]                                                          |
| pRP910        | Flag-Upf1 wild-type; cen; leu       | [17]                                                          |
| pRP1076       | gal-PGK1c142; cen; ura              | [4]                                                           |
| pRP2291       | Flag-Upf1 Mutant 3: Q166A E170A L175A W177A | This Study                                                   |
| pRP2292       | Flag-Upf1 Mutant 18: P111A D112A D114A D117A | This Study                                                   |
| pRP2293       | Flag-Upf1 Mutant 23: L115A Y123A     | This Study                                                     |
| pRP2294       | Flag-Upf1 Mutant 24: W177A           | This Study                                                     |
| pRP2295       | Flag-Upf1 Mutant 27: L115A Y123A W177A VVVL143AAAA | This Study                                                   |
| pRP609        | gal-PGK1c103; cen; ura              | [3]                                                           |
| pHF713        | prS316-HA-NMD2(X-5)                 | [8]; Gift from Alan Jacobson lab                               |
| pHF889        | prS316-mnd2-M13 (mutations 7958H, K963H, D987G, E1018G, K1024R, Y1027H) | [8]; Gift from Alan Jacobson lab                               |
| pHF961        | prS316-mnd2-M6-NE (mutations Y955N, K1010E) | [8]; Gift from Alan Jacobson lab                               |
| pHF964        | prS316-mnd2-M6-G (mutations E1070G) | [8]; Gift from Alan Jacobson lab                               |
| pHF893        | prS316-mnd2-M5 (mutations S997G, F1061S, I1079T) | [8]; Gift from Alan Jacobson lab                               |

Table 2. Plasmids used in this study.

DOI:10.1371/journal.pone.0026547.t002
Table 3. Oligos used in this study.

| Oligo | Sequence | Purpose |
|-------|----------|---------|
| oRP1542 | AATCTCAGGGAAGAACAAAGcagctTTGTGGTTGATACACTAA | Dcp2 Mutant 19: Mutations L255A K256A |
| oRP1543 | TTAGTGATACCCCAACAAACAAagctgTTGGTTTCCGCATAAGATT | Dcp2 Mutant 19: Mutations L255A K256A |
| oRP1544 | ATCAATTGAAATCTTCTGGgctGAACAAAGcagctTTGTGGTTGATACACTAA | Dcp2 Mutant 21: Mutations E252A L255A K256A |
| oRP1545 | TTAGTGATACCCCAACAAACAAagctgTTGGTTTCCGCATAAGATT | Dcp2 Mutant 21: Mutations E252A L255A K256A |
| oRP1546 | ACTGGGATACTGATCAGGgtcCTAATTAGgtcGACACAAACTgctCTACggtcATTAATAGGagcCCATTGATGACTCCAGT | Upf1 Mutant 3: Mutations Q166A E170A L175A W177A |
| oRP1547 | TCAGTTGTTGCTCTGGCAGctGAACAAAGcagctTTGTGGTTGATACACTAA | Upf1 Mutant 3: Mutations Q166A E170A L175A W177A |
| oRP1548 | TAAACATGTTCATTTAGcagctcATGAGGTGGAATATGTTATA | Upf1 Mutant 18: Mutations P111A D112A D114A D117A |
| oRP1549 | TATAACATTTCCCAAAACGGTgctcCCCTAAtgcAGATGAACTACGTTA | Upf1 Mutant 18: Mutations P111A D112A D114A D117A |
| oRP1550 | CTTCATACCAATCTGACTGcagctAGCAGCTCTGGAATATGIGTAAGACGT | Upf1 Mutant 23: Mutations L115A Y123A |
| oRP1551 | AGGTCTTACTGTCGACTGTgcACATCTAAAGAAGCTCCCGTGCAGTGAATAGAAGACGT | Upf1 Mutant 23: Mutations L115A Y123A |
| oRP1552 | AAGACAGAACAATTTATCTGGcagctCTCGAGAGAGAACAACAGTA | Upf1 Mutant 24: Mutation W177A |
| oRP1553 | TACGGTGGTGTCTGCGACAGctcAGATGAACTACGTTA | Upf1 Mutant 24: Mutation W177A |
| oRP1554 | TTTCCGCTAAATAGGACGGCGcagctcAGATGAACTACGTTA | Final construction of Upf1 Mutant 27: Mutations VVVL143AAAA |
| oRP1555 | GCACAAGGTATCTCTACAAAGgctgcagctgGGCTCAGTTAGGCCAAAGAAA | Final construction of Upf1 Mutant 27: Mutations VVVL143AAAA |

doI:10.1371/journal.pone.0026547.t003

to an NMD substrate and does not require further assistance from its associating factors. But, under different conditions, a cell may rely upon a broader decapping complex including Edc3 and Pat1, to dramatically increase the levels of NMD transcripts targeted for decapping and subsequent degradation.

Materials and Methods

Yeast strains

The yeast strains used in this study, and their genotypes, are found in Table 1. Strains yRP2834, yRP2835, and yRP2836 were constructed by homologous recombination in strain yRP2093. The deletion cassettes were PCR amplified from genomic DNA prepared from the Invitrogen/Resgen Collection strains, yRP2141 (upf2Δ pat1Δ), and yRP2067 (upf2Δ pat1Δ) using oligos complementary to the 5' and 3' untranslated regions for each open reading frame. Each PCR product was then transformed into yRP2093 and selected for transformants on media containing Geneticin. Yeast strain yRP2093 was constructed by standard laboratory procedure by crossing yRP2094 (MATa) with yRP2141 (MATa) and yRP2067 (MATa) strains containing specific Activating Domain (AD) or Binding Domain (BD) derivatives, respectively, and selection for diploids on drop-out media. Following this, the interaction was assessed using the β-galactosidase plate assay. Assessment of interaction between AD-Dcp2 (102–250) point mutants and BD-Upf1 Nt or AD-Edc3 FL and between BD-Upf1 point mutants and AD-Dcp2 (102–250), AD-Edc3 FL, or AD-Upf2 Ct was done in this manner. The second method relied upon mating of the MATa (yRP2094) and MATa (yRP2093) strains containing specific AD or BD derivatives, respectively, and selection for diploids on drop-out media. Following this, the interaction was assessed using the β-galactosidase plate assay. The method used for assessing interactions in yRP2093 and yRP2094 [4]. Briefly, cells were grown in selective media containing 2% to 3% D-glucose.
galactose until OD600 0.3–0.4. Due to the slow growth phenotype of yRP1752, this strain along with the wild-type yRP1040 was grown in selective media containing 2% galactose and 1% sucrose until OD600 0.3–0.4. Cells were then harvested and re-suspended in selective media containing 4% glucose to repress transcription of the galactose-inducible reporter transcripts. 2 ml aliquots were then taken at 12 time points over the course of one hour and frozen quickly in liquid nitrogen.

For assessment of CTH2 steady-state pre-mRNA and mRNA levels, cells were grown in selective media containing 2% glucose until OD600 0.3–0.4. Cells were then harvested and quickly frozen in liquid nitrogen.

For assessment of RNA half-lives and CTH2 steady-state levels, RNA was extracted by a hot phenol method. RNAs were analyzed by running 10 μg of each sample on a 1.5% formaldehyde agarose gel. PGK1c142 northern analysis was done using the radiolabeled oligo, oRP1300. PGK1c103 northern analysis was done using a gel. PGK1c142 northern analysis was done using the radiolabeled oligo, oRP252, which is specific for a nucleotide sequence ‘tag’ inserted in frame within PGK1, preventing detection of PGK1pG found within the strains used [3]. CTH2 pre-mRNA and mRNA transcripts were detected using the radiolabeled oligo, oRP1300. Radiolabeled signal was detected and quantified using a Typhoon phosphoimager (Molecular Dynamics). Determination of half-lives and steady-state levels was done by normalization of each lane to the stable 7S RNA using radiolabeled oligo, oRP100.

Acknowledgments

We thank John Gross for kindly providing us with the structure predictions and SASA values for S. cerevisiae Dcp2 and Upf1. We thank the entire Parker laboratory for their discussion and support of this research.

Author Contributions

Conceived and designed the experiments: KDS RP. Performed the experiments: KDS. Analyzed the data: KDS RP. Contributed reagents/materials/analysis tools: KDS RP. Wrote the paper: KDS RP.

References

1. Holbrook JA, Neu-Yilik G, Hentze MW, Kolozzik AE (2004) Nonsense-mediated decay approaches the clinic. Nat Genet 36: 801–806.
2. Rebbapragada I, Lykke-Andersen J (2009) Execution of nonsense-mediated mRNA decay: what defines a substrate? Curr Opin Cell Biol 21: 394–402.
3. Mulhied D, Parker R (1994) Premature translational termination triggers mRNA decapping. Nature 370: 576–581.
4. Cao D, Parker R (2003) Computational modeling and experimental analysis of nonsense-mediated decay in yeast. Cell 113: 535–545.
5. He F, Peltz SW, Donahue JL, Roshan M, Jacobson A (1993) Stabilization and ribosome association of unspliced pre-mRNAs in a yeast upf1 mutant. Proc Natl Acad Sci USA 90: 7034–7038.
6. He F, Jacobson A (1993) Identification of a novel component of the nonsense-mediated mRNA decay pathway by use of an interacting protein screen. Genes Dev 7: 437–444.
7. Maquat LE (2004) Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol 5: 89–99.
8. He F, Brown AH, Jacobson A (1996) Interaction between Nmd2p and Upf1p is required for activity but not for dominant-negative inhibition of the nonsense-mediated mRNA decay pathway in yeast. RNA 2: 153–170.
9. He F, Brown AH, Jacobson A (1997) Upf1p, Nmd2p, and Upf3p are interacting components of the yeast nonsense-mediated mRNA decay pathway. Mol Cell Biol 17: 1380–1394.
10. Wang W, Cajigas IJ, Peltz SW, Wilkinson MF, Gonzalez AE (2004) Nonsense-mediated decay approaches the clinic. Nat Genet 36: 801–806.
11. Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, et al. (2006) Global landscape of the yeast protein interactome. Mol Cell 26: 1077–1081.
12. Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, et al. (2006) Global landscape of the yeast protein interactome. Mol Cell 26: 1101–1113.
13. Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, et al. (2006) Global landscape of the yeast protein interactome. Mol Cell 26: 1307–1321.
14. Roper NS, Deshaies RJ (2004) Interactions between Upf1 and Edc3/Pat1 in Yeast. EMBO J 23: 2995–2996.
15. Radicella JP, Hanahan DJ (2004) Interactions between Upf1 and Edc3/Pat1 in Yeast. EMBO J 23: 2995–2996.
16. Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, et al. (2006) Global landscape of the yeast protein interactome. Mol Cell 26: 1077–1081.
17. Schwartz D, Decker CJ, Parker R (2003) The enhancer of decapping proteins, Ede1p and Ede2p, stimulate mRNA decay in Saccharomyces cerevisiae. Genetics 167: 729–739.
18. Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, et al. (2006) Global landscape of the yeast protein interactome. Mol Cell 26: 1077–1081.
19. Radicella JP, Hanahan DJ (2004) Interactions between Upf1 and Edc3/Pat1 in Yeast. EMBO J 23: 2995–2996.